Sanofi hits bullseye in phase III trial of treatment for RSV
Sanofi has completed a major phase III study of a drug for respiratory disease RSV in infants, and now, the company aims for official approval for the treatment.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY NIELSINE NIELSEN
Sanofi plans to start applying for approvals for the drug candidate nirsevimab over the course of 2022.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Ventures invests millions in Bavarian Nordic rival
For subscribers
